Healthcare
Live Price
Offline$162.99
+3.31% today
Window Change
+3.50%
Window
May 29, 2026 → Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars · May 29, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Revolution Medicines, Inc. (RVMD) is a Healthcare stock with a market cap of $31.44B and listed on NASDAQ. The stock last traded around $162.99 and up 3.5% across the available one-year price window (May 29, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -66.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -66.2%, free cash flow -60.9% with operating margin 0.0% and ROIC -56.8%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RVMD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RVMD
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RVMD Max Drawdown
-11.91%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RVMD and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$29.4M
-16.9% YoY
FY Net Income
-$187.1M
+24.8% YoY
Free Cash Flow
-$153.7M
+34.7% YoY
Revenue Growth
+0.0%
EPS Growth
-66.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 12M | 35M | 29M |
| Gross Profit | -17M | 0 | 12M | 35M | 29M |
| Operating Income | -1.2B | -690M | -487M | -258M | -188M |
| EBITDA | -1.1B | -678M | -478M | -249M | -180M |
| Net Income | -1.1B | -600M | -436M | -249M | -187M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 384M | 543M | 696M | 161M | 108M |
| Total Assets | 2.4B | 2.6B | 2.1B | 812M | 738M |
| Total Liabilities | 723M | 293M | 236M | 127M | 135M |
| Shareholder Equity | 1.6B | 2.3B | 1.8B | 685M | 603M |
| Total Debt | 159M | 136M | 88M | 64M | 67M |
| Net Debt | -225M | -407M | -608M | -97M | -42M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
147M
+34.4% YoY
Capital Expenditures
7M
+39.6% YoY
Free Cash Flow
154M
+34.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-63.1%
Debt / Equity
0.10x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.